Department of Clinical Physiology, Lund University, Lund University Hospital, Lund 221 85, Sweden.
Department of Pediatric Cardiology, Lund University, Lund University Hospital, Lund, Sweden.
Eur Heart J Cardiovasc Imaging. 2014 Dec;15(12):1350-7. doi: 10.1093/ehjci/jeu137. Epub 2014 Aug 19.
To determine if myocardial perfusion (MP) during hyperaemia is decreased in young patients with hypertrophic cardiomyopathy (HCM). Also, to determine if an MP decrease is associated with diastolic dysfunction, and to investigate if young subjects at risk of HCM show differences in MP compared with controls.
This study included 10 HCM patients (age 22.3 ± 6.4 years), 14 subjects at risk for HCM 'HCM risk' (age 18.9 ± 3.8 years), and 12 controls (age 22.8 ± 4.5 years). HCM patients were examined at rest and during hyperaemia (adenosine 140 µg/kg/min) with cardiovascular magnetic resonance (CMR) and echocardiography. MP was calculated as the ratio of coronary sinus flow and left ventricular mass (LVM) from CMR. Myocardial fibrosis was assessed using late gadolinium enhancement. Diastolic function was quantified with both echocardiography and CMR. At rest, MP (mL/min/g) was similar in the control, HCM risk, and HCM patients (0.8 ± 0.1, 1.0 ± 0.1, and 0.9 ± 0.1, respectively, P = ns). During adenosine, MP was lower in HCM patients (2.5 ± 0.4, P < 0.05) compared with both HCM risk (5.0 ± 0.5) and controls (3.9 ± 0.3). Subjects at HCM risk showed no significant difference in MP during adenosine compared with controls. One HCM patient showed mild diastolic dysfunction. Neither controls nor HCM risk individuals showed any sign of myocardial fibrosis, whereas 7/10 HCM patients had fibrosis (5 ± 1% of the total LVM).
Young individuals with HCM, but not those at risk, show decreased MP during hyperaemia compared with controls even in the absence of diastolic dysfunction or LV outflow obstruction. These results may suggest that microvascular disease contributes to the decreased MP in the investigated population.
确定在年轻肥厚型心肌病(HCM)患者中,充血时的心肌灌注(MP)是否降低。此外,确定 MP 降低是否与舒张功能障碍相关,并研究是否存在 HCM 风险的年轻受试者与对照组相比,在 MP 方面存在差异。
本研究纳入了 10 名 HCM 患者(年龄 22.3±6.4 岁)、14 名 HCM 风险患者(年龄 18.9±3.8 岁)和 12 名对照者(年龄 22.8±4.5 岁)。使用心血管磁共振(CMR)和超声心动图对 HCM 患者进行静息和充血(腺苷 140μg/kg/min)检查。MP 通过 CMR 计算为冠状窦流量与左心室质量(LVM)的比值。使用晚期钆增强评估心肌纤维化。通过超声心动图和 CMR 定量评估舒张功能。在静息状态下,对照组、HCM 风险患者和 HCM 患者的 MP(mL/min/g)相似(分别为 0.8±0.1、1.0±0.1 和 0.9±0.1,P=ns)。在腺苷作用下,HCM 患者的 MP 较低(2.5±0.4,P<0.05),与 HCM 风险(5.0±0.5)和对照组(3.9±0.3)相比均有显著差异。HCM 风险患者在腺苷作用下的 MP 与对照组相比无显著差异。一名 HCM 患者存在轻度舒张功能障碍。对照组和 HCM 风险个体均未出现心肌纤维化的任何迹象,而 7/10 的 HCM 患者存在纤维化(总 LVM 的 5±1%)。
即使在不存在舒张功能障碍或 LV 流出道梗阻的情况下,年轻的 HCM 患者而非存在 HCM 风险的个体在充血时的 MP 降低。这些结果可能表明微血管疾病导致了研究人群中 MP 的降低。